他拉唑帕尼(Talzenna)

[Talzenna’s Brief Introduction]

Talzenna, also known as [talazoparib] capsule, is the fourth generation PARP inhibitor developed by Pfizer, which belongs to targeted drugs.

[Indications of Talzenna]

This product is used for the treatment of breast cancer patients with hereditary BRCA1 or BRCA2 gene mutation.

[Talzenna Specification]

This product is packed in capsules, with specifications of 30 capsules per box, and each capsule contains 1mg of active ingredient.

[How to use Talzenna]

The recommended dosage is 1mg once a day, taken orally before or after meals.

[Notes for Talzenna]

This approval is based on the results of phase 3 clinical trials of an open label called EMBRACA. In this study, 431 patients were treated with talazoparib or the chemotherapy regimen chosen by doctors at a ratio of 2:1. All patients need to carry germline BRCA mutation.

The results showed that the progression-free survival (PFS) of patients treated with Talazorib was significantly longer than that of patients treated with chemotherapy. The median PFS in Talazorib group was 8.6 months, and that in chemotherapy group was 5.6 months (HR 0.54, 95% CI: 0.41, 0.71; p<0.0001）。 This means that talazoparib reduced the risk of disease progression by 46%.

Moreover, the objective remission rate in talazoparib group was 62.6%, which was more than twice that in chemotherapy group (27.2%) (p<0.0001).

[Adverse reaction of Talzenna]

The most common laboratory abnormalities (≥ 25%) are: hemoglobin, platelets, neutrophils, lymphocytes, leukocytes and calcium decrease. Glucose, alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase increased.

Adverse reactions (≥ 20%) were fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea and loss of appetite.